Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8+ T Cells in HCV-Seronegative Individuals: Implications for Vaccine Responses

ABSTRACT T cell responses play a critical role in controlling or clearing viruses. Therefore, strategies to prevent or treat infections include boosting T cell responses. T cells specific for various pathogens have been reported in unexposed individuals and an influence of such cells on the response toward vaccines is conceivable. However, little is known about their frequency, repertoire, and impact on vaccination. We performed a detailed characterization of CD8+ T cells specific to a hepatitis C virus (HCV) epitope (NS3-1073) in 121 HCV-seronegative individuals. We show that in vitro HCV NS3-1073-specific CD8+ T cell responses were rather abundantly detectable in one-third of HCV-seronegative individuals irrespective of risk factors for HCV exposure. Ex vivo, these NS3-1073-specific CD8+ T cells were found to be both naive and memory cells. Importantly, recognition of various peptides derived from unrelated viruses by NS3-1073-specific CD8+ T cells showed a considerable degree of T cell cross-reactivity, suggesting that they might in part originate from previous heterologous infections. Finally, we further provide evidence that preexisting NS3-1073-specific CD8+ T cells can impact the T cell response toward peptide vaccination. Healthy, vaccinated individuals who showed an in vitro response toward NS3-1073 already before vaccination displayed a more vigorous and earlier response toward the vaccine. IMPORTANCE Preventive and therapeutic vaccines are being developed for many viral infections and often aim on inducing T cell responses. Despite effective antiviral drugs against HCV, there is still a need for a preventive vaccine. However, the responses to vaccines can be highly variable among different individuals. Preexisting T cells in unexposed individuals could be one reason that helps to explain the variable T cell responses to vaccines. Based on our findings, we suggest that HCV CD8+ T cells are abundant in HCV-seronegative individuals but that their repertoire is highly diverse due to the involvement of both naive precursors and cross-reactive memory cells of different specificities, which can influence the response to vaccines. The data may emphasize the need to personalize immune-based therapies based on the individual's T cell repertoire that is present before the immune intervention.

[1]  Y. Naumov,et al.  Memory of mice and men: CD8+ T‐cell cross‐reactivity and heterologous immunity , 2006, Immunological reviews.

[2]  F. Celada,et al.  Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. , 2006, The Journal of clinical investigation.

[3]  Henrique Veiga-Fernandes,et al.  Response of naïve and memory CD8+ T cells to antigen stimulation in vivo , 2000, Nature Immunology.

[4]  R. Fujinami,et al.  Pathogenic epitopes, heterologous immunity and vaccine design , 2007, Nature Reviews Microbiology.

[5]  J. Ghrayeb,et al.  Memory CD8+ T Cells Are Required for Protection from Persistent Hepatitis C Virus Infection , 2003, The Journal of experimental medicine.

[6]  E. Gostick,et al.  Immunodominance of HLA-A2-Restricted Hepatitis C Virus-Specific CD8+ T Cell Responses Is Linked to Naïve-Precursor Frequency , 2011, Journal of Virology.

[7]  Mario Roederer,et al.  Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial , 2015, The Lancet.

[8]  Marialva Sinigaglia,et al.  Structural in silico analysis of cross-genotype-reactivity among naturally occurring HCV NS3-1073-variants in the context of HLA-A*02:01 allele. , 2011, Molecular immunology.

[9]  C. Klade,et al.  Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine. , 2010, Vaccine.

[10]  C. Klade,et al.  Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. , 2006, Vaccine.

[11]  A. Bertoletti,et al.  Heterologous T cell immunity in severe hepatitis C virus infection , 2005, The Journal of experimental medicine.

[12]  R. Welsh,et al.  Private specificities of CD8 T cell responses control patterns of heterologous immunity , 2005, The Journal of experimental medicine.

[13]  L. Kane Faculty Opinions recommendation of Distinct TCR signaling pathways drive proliferation and cytokine production in T cells. , 2013 .

[14]  M. Manns,et al.  Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073. , 2008, Vaccine.

[15]  Mutational escape of CD8+ T cell epitopes: implications for prevention and therapy of persistent hepatitis virus infections , 2014, Medical Microbiology and Immunology.

[16]  F. Chisari,et al.  Determinants of Viral Clearance and Persistence during Acute Hepatitis C Virus Infection , 2001, The Journal of experimental medicine.

[17]  M. Jenkins,et al.  The Role of Naive T Cell Precursor Frequency and Recruitment in Dictating Immune Response Magnitude , 2012, The Journal of Immunology.

[18]  A Sette,et al.  Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. , 1999, Journal of immunology.

[19]  B. Korber,et al.  Proteome-wide analysis of HIV-specific naive and memory CD4+ T cells in unexposed blood donors , 2014, The Journal of experimental medicine.

[20]  D. Douek,et al.  Unbiased Molecular Analysis of T Cell Receptor Expression Using Template‐Switch Anchored RT‐PCR , 2011, Current protocols in immunology.

[21]  M. Albert,et al.  Enumeration of human antigen-specific naive CD8+ T cells reveals conserved precursor frequencies. , 2010, Blood.

[22]  G. Nolan,et al.  Antigen-Dependent Integration of Opposing Proximal TCR-Signaling Cascades Determines the Functional Fate of T Lymphocytes , 2014, The Journal of Immunology.

[23]  J. Bennink,et al.  Cross-Reactivity between Hepatitis C Virus and Influenza A Virus Determinant-Specific Cytotoxic T Cells , 2001, Journal of Virology.

[24]  Raymond M. Welsh,et al.  No one is naive: the significance of heterologous T-cell immunity , 2002, Nature Reviews Immunology.

[25]  B. Walker,et al.  Defining the directionality and quality of influenza virus-specific CD8+ T cell cross-reactivity in individuals infected with hepatitis C virus. , 2008, The Journal of clinical investigation.

[26]  Atul J. Butte,et al.  Variation in the Human Immune System Is Largely Driven by Non-Heritable Influences , 2015, Cell.

[27]  S. Jameson,et al.  Preexisting high frequencies of memory CD8+ T cells favor rapid memory differentiation and preservation of proliferative potential upon boosting. , 2013, Immunity.

[28]  G. Rimmelzwaan,et al.  Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. , 2014, The Lancet. Infectious diseases.

[29]  M. Manns,et al.  Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response , 2007, Virology Journal.

[30]  Mark M. Davis,et al.  Deconstructing the Peptide-MHC Specificity of T Cell Recognition , 2014, Cell.

[31]  P. Doherty,et al.  Protective Efficacy of Cross-Reactive CD8+ T Cells Recognising Mutant Viral Epitopes Depends on Peptide-MHC-I Structural Interactions and T Cell Activation Threshold , 2010, PLoS pathogens.

[32]  Mark M. Davis,et al.  Antiviral memory phenotype T cells in unexposed adults , 2013, Immunological reviews.

[33]  Mark M Davis,et al.  Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults. , 2013, Immunity.

[34]  Yan Zhou,et al.  Will There Be a Vaccine to Prevent HCV Infection? , 2014, Seminars in Liver Disease.

[35]  Todd M. Allen,et al.  High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. , 2004, Gastroenterology.

[36]  F. Heinemann,et al.  Impact of Sequence Variation in a Dominant HLA-A*02-Restricted Epitope in Hepatitis C Virus on Priming and Cross-Reactivity of CD8+ T Cells , 2014, Journal of Virology.

[37]  M. Bonneville,et al.  Selection of high‐avidity CD8 T cells correlates with control of hepatitis C virus infection , 2008, Hepatology.

[38]  J. Sidney,et al.  Immunogenicity and Cross-Reactivity of a Representative Ancestral Sequence in Hepatitis C Virus Infection , 2012, The Journal of Immunology.

[39]  R. Welsh Private specificities of heterologous immunity. , 2006, Current opinion in immunology.

[40]  Mark M. Davis,et al.  A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory , 2014, Science Translational Medicine.

[41]  D. D. Des Jarlais,et al.  Hepatitis C virus‐specific T‐cell immune responses in seronegative injection drug users , 2009, Journal of viral hepatitis.

[42]  L. Watkin,et al.  CD8 T Cell Cross-Reactivity Networks Mediate Heterologous Immunity in Human EBV and Murine Vaccinia Virus Infections , 2010, The Journal of Immunology.

[43]  Marialva Sinigaglia,et al.  CrossTope: a curate repository of 3D structures of immunogenic peptide: MHC complexes , 2013, Database J. Biol. Databases Curation.

[44]  B. Walker,et al.  Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. , 1997, The Journal of infectious diseases.

[45]  A. Folgori,et al.  Cross‐reactivity of hepatitis C virus specific vaccine‐induced T cells at immunodominant epitopes , 2014, European journal of immunology.